Labcorp Holdings (LH) is in focus after peer reviewed studies highlighted its Metabolic Vulnerability Index and NIS2+ blood test for liver disease risk, alongside the nationwide, Medicare covered rollout of its RNA based ColoSense colorectal screening kit.

Those product updates sit alongside steady share price momentum, with Labcorp Holdings posting a 1-month share price return of 8.23% and a year to date share price return of 14.03%, while the 3-year total shareholder return of 41.36% points to meaningful longer term compounding.

If these diagnostics advances have you thinking more broadly about healthcare and AI, it could be a good moment to scan opportunities across 40 healthcare AI stocks

After a strong run in Labcorp Holdings, driven by new test launches and solid recent returns, the question now is whether the current valuation still leaves enough upside to justify fresh risk.

Most Popular Narrative: 7.5% Undervalued

Labcorp Holdings closed at $286.98 against a widely followed fair value estimate of about $310, which puts the current analyst narrative under the spotlight.

Labcorp's strategic collaborations and acquisitions, such as with Inspira Health and BioReference Health, are expected to drive revenue growth by expanding its presence in high-growth therapeutic areas like oncology and strengthening partnerships with health systems. The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings.

Analysts are effectively backing a story built on steady revenue increases, fatter margins and a richer earnings base, all discounted at just over 7%. Curious which specific growth and profitability assumptions have to hold up for that $310 fair value to make sense?

Result: Fair Value of $310.12 (UNDERVALUED)

However, that upside story for Labcorp Holdings still depends on tariffs, regulatory shifts and PAMA decisions not squeezing revenue or margins more than analysts currently factor in.

Next Steps

If the mixed sentiment around Labcorp Holdings has you weighing both the upside and the risks, it makes sense to move quickly and test the numbers against your own expectations using the full breakdown of 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Labcorp Holdings?

If Labcorp Holdings has sharpened your interest, do not stop here. Use the Simply Wall Street Screener now to line up your next set of potential candidates.

• Target dependable income by checking companies that appear in the 7 dividend fortresses.
• Spot potential value opportunities early by scanning the screener containing 18 high quality undiscovered gems.
• Prioritize capital preservation by focusing on companies highlighted in the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.